FDA Expands Approval of Pfizer’s TALZENNA- XTANDI Combination
The FDA approved the TALZENNA and XTANDI combination for men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Story updates
05:41:16 PM UTC
SquawkNews
TALZENNA plus XTANDI is now approved for HRR gene-mutated metastatic androgen pathway modulation-naï
05:41:25 PM UTC
SquawkNews
FDA approved Talzenna (talazoparib) plus Xtandi (enzalutamide) for HRR gene—mutated metastatic hormone—sensitive prostate cancer, expanding Pfizer’s prior approval in later—line disease. Decision followed Priority Review supported by Phase 3 TALAPRO—3.Material DetailsContext by AI AnalystThis is a…
05:44:24 PM UTC
SquawkNews
FDA approved TALZENNA plus XTANDI for men with HRR gene-mutated metastatic androgen pathway modulati
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC…